Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T06:44:55.005Z Has data issue: false hasContentIssue false
  • English
  • Français

Powder X-ray crystallography of gallium 3-hydroxy-4-pyronates

Published online by Cambridge University Press:  10 January 2013

Lawrence R. Bernstein
Lawrence R. Bernstein
Affiliation:
Terrametrix, 107 Gilbert Avenue, Menlo Park, California 94025, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Two complexes of gallium with 3-hydroxy-4-pyrones were synthesized as potential pharmaceutical compounds for oral administration. These compounds were analyzed by powder X-ray diffraction followed by computer indexing of the data. The first compound, tris(3-hydroxy-2-methyl-4-pyronato)gallium [Ga(C6H5O3)3], was found to be orthorhombic, a = 18.500(2), b = 16.948(2), c = 12.012(2) Å, V = 3766(1) Å3, Z = 8, Dm = 1.56(5), Dx = 1.570. The compound appears closely analogous to a similar compound containing Al instead of Ga, which crystallizes in space group Pbca. The second compound, tris(3-hydroxy-2-ethyl-4-pyronato)gallium [Ga(C7H7O3)3], was found to be monoclinic, a = 31.634(2), b = 8.7662(5), c = 7.8982(5) Å, β = 103.240(6)°, V = 2132.0(5) Å3, Z = 4, Dm = 1.50(5), Dx = 1.517, with a primitive space group.

Type
Research Article
Information
Powder Diffraction , Volume 10 , Issue 2 , June 1995 , pp. 140 - 142
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bernstein, L. R. (1993). “Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones,” U.S. Patent 5,258,376.Google Scholar
Finnegan, M. M., Rettig, S. J., and Orvig, C. (1986). “A neutral watersoluble aluminum complex of neurological interest,” J. Am. Chem. Soc. 108, 5033–5035.CrossRefGoogle Scholar
Matkovic, V., Apseloff, G., Shepard, D. R., and Gerber, N. (1990). “Use of gallium to treat Paget's disease of bone: a pilot study,” The Lancet 335, 72–75.Google Scholar
Warrell, R. P. Jr., and Bockman, R. S. (1985). “Use of gallium salts to treat disorders of calcium homeostatis,” U.S. Patent 4,529,593.Google Scholar
Warrell, R. P. Jr., and Bockman, R. S. (1989). “Gallium in the treatment of hypercalcemia and bone metastasis,” in Important Advances in Oncology 1989, edited by DeVita, V. T., Hellman, S., and Rosenberg, S. A. (Lippincott, Philadelphia), pp. 205–220.Google Scholar
Warrell, R. P. Jr., Bosco, B., Weinerman, S., Levine, B., Lane, J., and Bockman, R. S. (1990). “Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis,” Ann. Internal Med. 113, 847–851.CrossRefGoogle ScholarPubMed
Warrell, R. P. Jr., Lovett, D., Dilmanian, F. A., Schneider, R., and Heelan, R. T. (1993). “Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study,” J. Clin. Oncol. 11, 2443–2450.CrossRefGoogle ScholarPubMed
Weik, J. K., Stephens, R. L., Baker, L. H., and Jones, S. E. (1983). “Galliumnitrate in malignant lymphoma: a Southwest Oncology Group study,” Cancer Treatment Rep. 67, 823–825.Google Scholar
Werner, P.-E., Eriksson, L., and Westdahl, M. (1985). “TREOR, a semiexhaustive trial-and-error powder indexing program for all symmetries,” J. Appl. Crystallogr. 18, 367–370.CrossRefGoogle Scholar